The U.S. FDA approved the first of its kind targeted RNA-based therapy Onpattro (patisiran) to treat peripheral nerve disease (polyneuropathy) caused from hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. This is the first FDA approved treatment in a new class of drugs called small interfering ribonucleic acid (siRNA) treatment. Read more here.
- Keep Your Genes On: How to Set Patients’ Expectations of PGx Testing
- FDA Approves a New Version of OTC Inhaler Primatene Mist
- New Physical Activity Guidelines for Americans: “Move more, and sit less”
- FDA Announces an Emergency Use Authorization for “Fingerstick” Ebola Test that Uses a Portable Battery Reader
- French Study finds Association with Organic Food Consumption and Reduced Risk of Cancer